{
    "pmcid": "7820838",
    "qa_pairs": {
        "How do multivalent nanobody constructs compare to monomeric forms in terms of neutralizing activity?": [
            "They show up to two-thousand-fold improvement in efficacy.",
            "They show no significant difference in efficacy.",
            "They are less effective than monomeric forms.",
            "They have a ten-fold decrease in efficacy."
        ],
        "What is a key advantage of camelid-derived nanobodies in targeting the SARS-CoV-2 spike protein?": [
            "Their ability to bind to cryptic epitopes inaccessible to conventional antibodies.",
            "Their larger size compared to conventional antibodies.",
            "Their inability to be engineered into multivalent formats.",
            "Their exclusive production in eukaryotic systems."
        ],
        "What is a potential delivery method for nanobodies due to their stability and small size?": [
            "Inhalation delivery directly targeting the lungs.",
            "Intravenous injection for systemic exposure.",
            "Oral administration for gastrointestinal absorption.",
            "Topical application for skin absorption."
        ],
        "What is the role of the S1 subunit of the SARS-CoV-2 spike protein?": [
            "It contains the receptor-binding domain that interacts with ACE2.",
            "It facilitates membrane fusion with host cells.",
            "It is responsible for viral replication.",
            "It provides structural support to the virus."
        ],
        "What technology is used to rapidly produce and engineer nanobodies for high-affinity binders?": [
            "Phage display technology.",
            "CRISPR-Cas9 gene editing.",
            "RNA interference.",
            "Polymerase chain reaction (PCR)."
        ]
    }
}